Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist

Lipids

Volumn 52, Issue 4, 2017, Pages 335-344

  Fujita, Kyosuke ^a   Iguchi, Yusuke ^b   Une, Mizuho ^b   Watanabe, Shiro ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

Cholesterol ester; Fatty acid; Sterol regulatory element binding protein 1c; Triglyceride

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA MURICHOLIC ACID; BETA MURICHOLIC ACID; CHENODEOXYCHOLIC ACID; CHOLESTEROL; CHOLIC ACID DERIVATIVE; DEOXYCHOLIC ACID; FARNESOID X RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; MURICHOLIC ACID; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL CELL; ARTICLE; BODY WEIGHT; CHEMICAL COMPOSITION; CHOLESTEROL LIVER LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; FATTY ACID ANALYSIS; FOOD INTAKE; IN VITRO STUDY; LIPID LIVER LEVEL; LIPOGENESIS; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TRANSACTIVATION ASSAY; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM;

ANIMALS; CELL LINE; CHENODEOXYCHOLIC ACID; CHOLIC ACIDS; DEOXYCHOLIC ACID; GENE EXPRESSION REGULATION; LIPOGENESIS; LIVER; MALE; MICE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; URSODEOXYCHOLIC ACID;

EID: 85015680667     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-017-4242-5     Document Type: Article

References (32)

1. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B (1999) Identification of a nuclear receptor for bile acids. Science 284(5418):1362–1365
2. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284(5418):1365–1368
3. Li T, Chiang JY (2014) Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 66:948–983
4. Kuipers F, Bloks VW, Groen AK (2014) Beyond intestinal soap—bile acids in metabolic control. Nat Rev Endocrinol 10:488–498
5. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ (2001) Nuclear receptors and lipid physiology: opening the X-files. Science 294:1866–1870
6. Hoeke MO, Heegsma J, Hoekstra M, Moshage H, Faber KN (2014) Human FXR regulates SHP expression through direct binding to an LRH-1 binding site, independent of an IR-1 and LRH-1. PLoS One 9:e88011
7. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J (2004) Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113:1408–1418
8. Shen LL, Liu H, Peng J, Gan L, Lu L, Zhang Q, Li L, He F, Jiang Y (2011) Effects of farnesoid X receptor on the expression of the fatty acid synthetase and hepatic lipase. Mol Biol Rep 38:553–559
9. Bilz S, Samuel V, Morino K, Savage D, Choi CS, Shulman GI (2006) Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. Am J Physiol Endocrinol Metab 290:E716–E722
10. Buko VU, Kuzmitskaya-Nikolaeva IA, Naruta EE, Lukivskaya OY, Kirko SN, Tauschel HD (2011) Ursodeoxycholic acid dose-dependently improves liver injury in rats fed a methionine- and choline-deficient diet. Hepatol Res 41:647–659
11. Mahmoud AA, Elshazly SM (2014) Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats. PLoS One 9:e106993
12. Oh AR, Bae JS, Lee J, Shin E, Oh BC, Park SC, Cha JY (2016) Ursodeoxycholic acid decreases age-related adiposity and inflammation in mice. BMB Rep 49:105–110
13. Quintero P, Pizarro M, Solís N, Arab JP, Padilla O, Riquelme A, Arrese M (2014) Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion. J Physiol Biochem 70:667–674
14. Tsuchida T, Shiraishi M, Ohta T, Sakai K, Ishii S (2012) Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice. Metabolism 61:944–953
15. Mueller M, Thorell A, Claudel T, Jha P, Koefeler H, Lackner C, Hoesel B, Fauler G, Stojakovic T, Einarsson C, Marschall HU, Trauner M (2015) Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol 62:1398–1404
16. Watanabe S, Fujita K (2014) Dietary hyodeoxycholic acid exerts hypolipidemic effects by reducing farnesoid X receptor antagonist bile acids in mouse enterohepatic tissues. Lipids 49:963–973
17. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ (2002) Vitamin D receptor as an intestinal bile acid sensor. Science 296(5571):1313–1316
18. Hu X, Bonde Y, Eggertsen G, Rudling M (2014) Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism. J Intern Med 275:27–38
19. Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F (2013) Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17:225–235
20. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911–917
21. Kunishima M, Kawachi C, Hioki K, Terao K, Tani S (2001) Formation of carboxamides by direct condensation of carboxylic acids and amines in alcohols using a new alcohol- and water-soluble condensing agent: DMT-MM. Tetrahedron 57:1551–1558
22. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, Goldstein JL (2003) Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci USA 100:12027–12032
23. De Leon MP, Carulli N, Loria P, Iori R, Zironi (1980) Cholesterol absorption during bile acid feeding. Effect of ursodeoxycholic acid (UDCA) administration. Gastroenterol 78:214–219
24. Uchida K, Akiyoshi T, Igimi H, Takase H, Nomura Y, Ishihara S (1991) Differential effects of ursodeoxycholic acid and ursocholic acid on the formation of biliary cholesterol crustals in mice. Lipids 26:526–530
25. Serhan CN, Yacoubian S, Yang R (2008) Anti-inflammatory and pro-resolving lipid mediators. Annu Rev Pathol 3:279–312
26. Lew JL, Zhao A, Yu J, Huang L, De Pedro N, Peláez F, Wright SD, Cui J (2004) The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J Biol Chem 279:8856–8861
27. Jiang C, Xie C, Lv Y, Li J, Krausz KW, Shi J, Brocker CN, Desai D, Amin SG, Bisson WH, Liu Y, Gavrilova O, Patterson AD, Gonzalez FJ (2015) Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 6:10166. doi:10.1038/ncomms10166
28. Nie Y-F, Hu J, Yan X-H (2015) Cross-talk between bile acids and intestinal microbiota in host metabolism and health. J Zhejiang Univ Sci B 16:436–446
29. Li T, Matozel M, Boehme S, Kong B, Nilsson LM, Guo G, Ellis E, Chiang JYL (2011) Overexpression of cholesterol 7α-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology 53:996–1006
30. Fedorowski T, Salen G, Calallilo A, Tint GS, Mosbach EH, Hall JC (1977) Metabolism of ursodeoxycholic acid in man. Gastroenterology 73:1131–1137
31. García-Cañaveras JC, Donato MT, Castell JV, Lahoz A (2012) Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. J Lipid Res 53:2231–2241
32. Lee JM, Gang GT, Kim DK, Kim YD, Koo SH, Lee CH, Choi HS (2014) Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE. J Biol Chem 289:1079–1091